Martin Indorf

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg, Walter L. Vervenne, Maria De Santis et al. · European Urology · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16

Salt tolerance (STO), a stress‐related protein, has a major role in light signalling

Martin Indorf, Julio Cordero, Gunther Neuhaus et al. · The Plant Journal · 2007 · 141 citations · Full text

Life Sciences, Plant Biology, Plant Sciences +16

Nuclear Localization and Interaction with COP1 Are Required for STO/BBX24 Function during Photomorphogenesis  

Huili Yan, Katrin Marquardt, Martin Indorf et al. · PLANT PHYSIOLOGY · 2011 · 115 citations · Full text

Life Sciences, Biology, Plant Sciences +13

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Maurice Stephan Michel, Walter L. Vervenne, Maria De Santis et al. · Journal of Clinical Oncology · 2014 · 44 citations

Medicine, Oncology, Pharmacotherapy +17

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Margitta Retz, Jens Bedke, Martin Bögemann et al. · European Journal of Cancer · 2018 · 32 citations

Medicine, Oncology, Pharmacology +12